88 filings
Page 3 of 5
8-K
ldsd6t
5 Aug 21
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
7:28am
8-K
wppj0mvzn 8lpe
17 Jun 21
Other Events
8:17am
8-K
w2n cude3j0
14 Jun 21
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
lxvgnzdm
13 May 21
AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update
7:15am
8-K
un3v2j
3 May 21
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01
7:24am
8-K
p9edqgd55em7j
23 Mar 21
Regulation FD Disclosure
8:03am
8-K
sx5cyp
18 Mar 21
AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
7:06am
8-K
p30790cdqg lmenvcqa
8 Feb 21
Regulation FD Disclosure
7:57am
8-K
386jr3doirv mz7kbfv
11 Jan 21
Regulation FD Disclosure
7:01am
8-K
p1isx6c8qt zcb6jk
20 Nov 20
AVROBIO Announces Proposed Public Offering of Common Stock
4:08pm
8-K
0yf84y4o
17 Nov 20
Other Events
9:07am
8-K
82oc6de 56xvxugvj
17 Nov 20
Three months post-gene therapy, first patient in Gaucher trial shows reductions in the toxic metabolite
7:39am
8-K
1eb4c03 37v5ggr4
5 Nov 20
AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update
7:18am
8-K
jxazk9ueiaqwt6rovu
21 Oct 20
AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
8:19am
8-K
eye9d7ur 9phsbc
6 Oct 20
Regulation FD Disclosure
8:29am
8-K
xs8xg6gv
5 Oct 20
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
7:10am
8-K
lv9u2e30sy5zz
6 Aug 20
AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update
7:07am
8-K
ykr55un8
6 Jul 20
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
7:35am
8-K
opyehu2
16 Jun 20
Regulation FD Disclosure
8:24am
8-K
5052lf7
9 Jun 20
Submission of Matters to a Vote of Security Holders
4:30pm